Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Basic research into Parkinson’s

06.05.2004


Parkinson’s disease was first described in 1817 by the London physician James Parkinson. A great amount of research has been carried out since that time but the fundamental causes of the disease remain unresolved. Some time ago now researchers found that a neurotransmitter, dopamine, played a key role in this illness. This is why the majority of treatments used today to counter Parkinson’s increase the level of dopamine in the brain exciting the receptors of this neurotransmitter.

Animal models

Parkinson’s disease affects certain concrete cerebral nuclei in the human brain. These nuclei are the striated and the dark matter, nuclei which are related to the motor system. Parkinson’s disease specifically affects those neurones located between these cerebral nuclei.



So, when animals are used as models in order to analyse the illness, rats for example, lesions appear precisely at the location of these cerebral nuclei. The procedure involves introducing a toxic substance into specific co-ordinates of the rat’s brain, but only into one hemisphere thereof, the other remaining as a control or reference. In other words, so that the Parkinson’s is generated solely on one side of the animal’s brain.

Once the animal has recovered from the operation, after approximately one month, the analyses can begin. On the one hand, the behaviour of the animal is studied and analysed – the visible, external effects and, on the other, the effects of medication. In order to analyse the effects of the medication habitually used to treat the ailment, these medicines are administered and subsequently the electro-physiological activity of the brain is measured, i.e. the activity of the neurones. In this way it is intended to discover the medication most suitable to stop the progress of the disease.

Mild Parkinson’s

By the time Parkinson’s symptoms appear in humans, cerebral lesions are quite serious and the disease passed the point of no return. However, apparently, if the disease is managed to be detected at the early stages and applying a neurone protection treatment, the illness can be halted.

But, in this case, the validity of the medicines used presently is called into question. For example, the effects that the currently most commonly used treatment, levodopa. That is, it is not clear whether levodopa administered in the early stages of Parkinson’s is neuroprotector or neurotoxic. To this end, in order to analyse, amongst other factors, the effects that levodopa produce in the early stages of Parkinson’s, a model of mild Parkinson’s has been developed at the Leioa campus of the University of the Basque Country.

Obtaining rats with mild Parkinson’s is no easy task, given that the exact dose of the toxic substance has to be injected into the animal brain. Once a rat with mild Parkinson’s has been obtained, the usual medicines are administered and the animal monitored to see if there is a differentiated evolution in the disease or not. Thus, according the Leioa investigation, the effect of the medication is totally different depending if the rat is healthy, if it has mild Parkinson’s, or if the disease is advanced.

So, definite conclusions have yet to drawn, Moreover, in the case of Parkinson’s, soon we will have to start dealing with gene therapy or therapeutic cloning, given that these are the future paths to follow in order to counter the disease, according to the experts.

Garazi Andonegi | Basque research
Further information:
http://www.basqueresearch.com/berria_irakurri.asp?Gelaxka=1_1&Berri_Kod=461&hizk=I
http://www.ehu.es

More articles from Health and Medicine:

nachricht Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Simple processing technique could cut cost of organic PV and wearable electronics

06.12.2016 | Materials Sciences

3-D printed kidney phantoms aid nuclear medicine dosing calibration

06.12.2016 | Medical Engineering

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>